[1] KU M S, DUBIN W. A biopharmaceutical classification-basedright-first-timeformulation approach to reduce human pharmacokinetic variability andproject cycle time from first-in-human to clinical proof-of-concept [J]. Pharm Dev Technol, 2010,17 (3):285-302.
[2] LIN C, CHEN F, YE T, et al. A novel oral delivery system consisting in drug-in cyclodextrin-in nanostructured lipid carriers for poorly water-soluble drug:vinpocetine [J]. Int J Pharm, 2014, 465 (1-2):90-96.
[3] MIYAKO Y, KHALEF N, MATSUZAKI K, et al. Solubility enhancement of hydrophobic compounds by cosolvents:role of solute hydrophobicity on the solubilization effect [J]. Int J Pharm, 2010, 393 (1-2):48-54.
[4] BEAULIEU P L, DE MARTE J, GAMEAU M, et al. A prodrug strategy for the oral delivery of a poorly soluble HCV NS5B thumb pocket 1 polymerase inhibitor using self-emulsifying drug delivery systems (SEDDS) [J]. Bioorg Med Chem Lett, 2015, 25 (2):210-215.
[5] FU Q, KOU L F, GONG C, et al. Relationship between dissolution and bioavailability for nimodipine colloidal dispersions:the critical size in improving bioavailability [J]. Int J Pharm, 2012, 427 (2):358-364.
[6] HINTZEN F, PERERA G, HAUPTSTEIN S, et al. In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin [J]. Int J Pharm, 2014, 29 (1-2):20-26.
[7] ELOY J O, MARCHETTI J M. Solid dispersions containing ursolic acid in Poloxamer 407 and PEG 6000: a comparative study of fusion and solvent methods [J]. Powder Technol, 2014, 253:98-106.
[8] CHIOU W L, RIEGELMAN S. Pharmaceutical applications of solid dispersion systems [J]. J Pharm Sci, 1971, 60 (9):1281-1302.
[9] VO C L, PARK C, LEE B J. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs [J]. Eur J Pharm Biopharm, 2013, 85 (3):799-813.
[10] VASCONCELOS T, SARMENTO B, COSTA P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs [J]. Drug Discov Today, 2007, 12 (23-24):1068-1075.
[11] MURGIA S, FADDA P, COLAFEMMINA G, et al. Characterization of the Solutol?HS 15/water phase diagram and the impact of the Δ⁹-tetra-hydro- cannabinol solubilization [J]. J Colloid Interf Sci, 2013, 390(1):129-136.
[12] COON J S, KNUDSON W, CLODFELTER K, et al. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance [J]. Cancer Res, 1991, 51 (3):897-902.
[13] ALANI A W, RAO D A, SEIDEL R, et al. The effect of novel surfactants and Solutol? HS 15 on paclitaxel aqueous solubility and permeability across a Caco-2 monolayer [J]. J Pharm Sci, 2010, 99 (8):3473-3485.
[14] SEO S W, HAN H K, CHUN M K, et al. Preparation and pharmacokinetic evaluation of curcumin solid dispersion using Solutol? HS15 as a carrier [J]. Int J Pharm, 2012, 424 (1-2):18-25.
[15] PUNCOCHOVá K, VUKOSAVLJEVIC B, HANU? J, et al. Non-invasive insight into the release mechanisms of a poorly soluble drug from amorphous solid dispersions by confocal Raman microscopy [J]. Eur J Pharm Biopharm, 2016, 101:119-125.
[16] GUTH F, SCHMELLER T, KOLTER K. Characterization Requirements for New Excipients [M]. France:The International Pharmaceutical Excipients Council Europe Annual Seminar, Cannes, 2011.
[17] HOMAYOUNI A, SADEGHI F, VARSHOSAZ J, et al. Promising dissolution enhancement effect of Soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques [J]. Colloid Surface B, 2014, 122:591-600.
[18] HARDUNG H, DJURIC D, ALI S. Combining HME & solubilization:soluplus?-the solid solution [J]. Drug Deliv Technol, 2010, 10 (3):20-27.
[19] LINN M, COLLNOT E M, DIURIC D, et al. Soluplus?as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo [J]. Eur J Pharm Sci, 2012, 45 (3):336-343.
[20] ZHANG K R, YU H X, LUO Q, et al. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension [J]. Eur J Pharm Biopharm, 2013, 85 (3):1285-1292.
[21] ONOUE S, SUZUKI H, KOJO Y, et al. Self-micellizing solid dispersion of cyclosporine A with improved dissolution and oral bioavailability[J]. Eur J Pharm Sci, 2014, 62:16-22.
[22] ONOUE S, KOJO Y, SUZUKI H, et al. Development of novel solid dispersion of tranilast using amphiphilic block copolymer for improved oral bioavailability [J]. Int J Pharm, 2013, 452 (1-2):220-226.
[23] MANIRUZZAMAN M, NAIR A, SCOUTARIS N, et al. One-step continuous extrusion process for the manufacturing of solid dispersions [J]. Int J Pharm, 2015, 496 (1):42-51.
[24] SHAH A, SERAJUDDIN A T M. Conversion of solid dispersion prepared by acid-base interaction into free-flowing and tabletable powder by using Neusilin?US2 [J]. Int J Pharm, 2015, 484 (1-2):172-180.
[25] HU Y, ZHI Z, ZHAO Q, et al. 3D cubic mesoporous silica microsphere as a carrier for poorly soluble drug carvedilol [J]. Micropor Mesopor Mat, 2012, 147 (1):94-101.
[26] THOMAS M J K, SLIPPER I, WALUNJ A, et al. Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles [J]. Int J Pharm, 2009, 387 (1-2):272-277.
[27] WANG Z H, CHEN B, QUAN G, et al. Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica [J]. Int J Nanomed, 2012, 7:5807-5818.
[28] LI J, MIAO X Q, CHEN T K, et al. Preparation and characterization of pelletized solid dispersion of resveratrol with mesoporous silica microparticles to improve dissolution by fluid-bed coating techniques [J]. Asian J Pharm Sci, 2015, doi:10.1016/j.ajps.2015.10.030.
[29] ZHANG P, FORSGREN J, STR?MME M. Stabilisation of amorphous ibuprofen in Upsalite, a mesoporous magnesium carbonate, as an approach to increasing the aqueous solubility of poorly soluble drugs [J]. Int J Pharm, 2014, 472 (1-2):185-191.
[30] YASUJI T, TAKEUCHI H, KAWASHIMA Y. Particle design of poorly water-soluble drug substances using supercritical fluid technologies [J]. Adv Drug Deliv Rev, 2008, 60 (3):388-398.
[31] CHEN A Z, LI Y, CHAU F T, et al. Application of organic nonsolvent in the process of solution-enhanced dispersion by supercritical CO₂ to prepare puerarin fine particles [J]. J Supercrit Fluid, 2009, 49 (3):394-402.
[32] DE ZORDI N, MONEGHINI M, KIKIC I, et al. Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions [J]. Eur J Pharm Biopharm, 2012, 81 (1):131-141.
[33] ADELI E. A comparative evaluation between utilizing SAS supercritical fluid technique and solvent evaporation method in preparation of Azithromycin solid dispersions for dissolution rate enhancement [J]. J Supercrit Fluid, 2014, 87:9-21.
[34] YU D G, HU M H, ZHOU W, et al. Electrospun ketoprofen sustained release nanofibers prepared using coaxial electrospinning[J]. Appl Mech Mater, 2013, 395-396:138-143.
[35] NAGY Z K, BALOGH A, DéMUTH B, et al. High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole [J]. Int J Pharm, 2015, 480 (1-2):137-142.
[36] DéMUTH B, FARKAS A, PATAKI H, et al. Detailed stability investigation of amorphous solid dispersions prepared by single-needle and high speed electrospinning [J]. Int J Pharm, 2016, 498 (1-2):234-244.
[37] BASSI P, KAUR G. pH modulation:a mechanism to obtain pH-independent drug release [J]. Expert Opin Drug Del, 2010, 7 (7):845-857.
[38] YANG M Y, HE S L, FAN Y Z, et al. Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug:preparation, characterization and evaluation in vivo [J]. Int J Pharm, 2014, 475 (1-2):97-109.
[39] MARASINI N, TRAN T H, POUDEL B K, et al. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique [J]. Int J Pharm, 2013, 441 (1-2):424-432.